43rd week of 2008 patent applcation highlights part 41 |
Patent application number | Title | Published |
20080260683 | Rodenticide - The invention relates to the systemic insecticide fipronil in conjunction with a rodenticide used for manufacture of a bait composition to provide a lethal effect on fleas and/or ticks and a host rodent, following ingestion of the bait composition by the host rodent. Preferred rodenticides are brodifacoum, difethialone, flocoumafen, bromadiolone and mixtures thereof. The invention also relates to rodenticidal bait compositions and to a method of killing ticks and a host rodent by providing for ingestion to the rodent, a bait composition comprising an effective amount of a rodenticide and an acaricidally effective amount of fipronil. | 2008-10-23 |
20080260684 | Method for the Purification of G-Csf - The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively. | 2008-10-23 |
20080260685 | PRODRUGS OF CC-1065 ANALOGS - Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytotoxic drugs in a targeted fashion. | 2008-10-23 |
20080260686 | METHODS OF USING IL-31 TO TREAT AIRWAY HYPER-RESPONSIVENESS AND ASTHMA - Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state. | 2008-10-23 |
20080260687 | SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY - A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder. | 2008-10-23 |
20080260688 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 2008-10-23 |
20080260689 | PEPTIDES FOR ACTIVE ANTI-CYTOKINE IMMUNIZATION - Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said cytokine, the spacing d being evaluated on the basis of structural data, derivatives, immunogenic compounds comprising them, use of a peptide or peptide derivative or immunogenic compound for the preparation of a curative or preventative medicament intended for the treatment or prevention of diseases linked to an excess or to the presence of cytokines or for the treatment of an auto-immune disease and pharmaceutical compositions which contain at least one abovementioned peptide or peptide derivative or immunogenic compound as active ingredient. | 2008-10-23 |
20080260690 | Interferon in Influenza - The use of an interferon (IFN) for the manufacture of a medicament for treatment and/or prevention of influenza, preferably avian influenza, is described in the present invention. | 2008-10-23 |
20080260691 | Prodrugs of Ribavirin with Improved Hepatic Delivery - The present invention relates ribavirin delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to ribavarin and methods for administering conjugated ribavirin compositions. | 2008-10-23 |
20080260692 | Spirulin Composition Rich in Active Principles, Method for Obtaining Same and Use Thereof - The invention relates to a spirulina combination composed of at least two distinct strain types from the genus | 2008-10-23 |
20080260693 | METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPED RETROVIRUSES USING ENVELOPE GLYCOPROTEINS FROM LYMPHOCYTIC CHORIOMENINGITIS VIRUS (LCMV) - The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy. | 2008-10-23 |
20080260694 | Multipotential Expanded Mesenchymal Precursor Cell Progeny (Memp) and Uses Thereof - The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1 | 2008-10-23 |
20080260695 | Composition for prevention and/or treatment of cancer - The invention relates to a composition for use in the prevention and treatment of cancer. The composition includes fermented soy extract, oligomeric proanthocyanidin, epigallocatiechin gallate, spirulina, curcumin and | 2008-10-23 |
20080260696 | Method for decreasing inflammation and oxidative stress in mammals - The present invention is directed to a method for decreasing inflammation and oxidative stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to decrease a level of an oxidized glutathione and/or increase the ration of reduced glutathione to oxidized glutathione in the blood of the mammal subsequent to administration of the glucose anti-metabolite. | 2008-10-23 |
20080260697 | Bacterial Management in Animal Holding Systems - The present invention is directed to method for reducing a population of a target pathogen in an animal or within a feedlot. The method involves administering one or more than one controlled release bacteriophage strain or phage component, or both, to the animal, so that the one, or more than one bacteriophage strain is released in vivo and adsorbs to the one or more than one target pathogen, thereby reducing the one, or more than one pathogen from the animal. The controlled release bacteriophage strain or phage component may be administered as a treatment dose prior to further processing of the animal, a treatment dose followed by a maintenance dose, or a maintenance dose, to manage feedlot target pathogens. | 2008-10-23 |
20080260698 | Chimeric sindbis-western equine encephalitis virus and uses thereof - The present invention discloses a chimeric alphavirus comprising a Sindbis virus cDNA fragment, an Eastern equine encephalitis virus cDNA fragment, a Western equine encephalitis virus cDNA fragment or a combination thereof. The present also discloses the use of this chimeric alphavirus as vaccines and in serological and diagnostic assays. | 2008-10-23 |
20080260699 | Adminstration of intact mammalian cells to the brain by the intranasal route - The present invention provides an intranasal method for delivery of intact mammalian cells to the brain for treatment of neurological deficits. This approach applies an intranasal instillation to directly administer cells to the brain, and is useful as therapy for patients with neurological deficit or those who may benefit from cellular therapy as a result of stroke, Alzheimer's, Parkinson's, diabetes, traumatic injury, surgery, cancer, or other diseases of the brain. This non-invasive method of delivering neuronal cells is desirable and safe. | 2008-10-23 |
20080260700 | GENERATION OF PANCREATIC ENDOCRINE CELLS FROM PRIMARY DUCT CELL CULTURES AND METHODS OF USE FOR TREATMENT OF DIABETES - The invention is directed to spontaneously immortalized pancreatic duct cells and methods for generating pancreatic endocrine cells from spontaneously immortalized pancreatic duct cells that express the transcription factors Pdx1 and FoxO1. The invention also provides for methods for treating beta cell failure, the method comprising administering to a subject an effective amount of spontaneously immortalized pancreatic duct cells expressing a mutated version FoxO1. | 2008-10-23 |
20080260701 | ANTI-ANGIOGENIC CELLULAR AGENT FOR CANCER THERAPY - The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors. | 2008-10-23 |
20080260702 | Treatment of Retinopathies Using Gfra3 Agonists - The present invention relates to the use of GFRα3 agonists for the treatment of disorders of the retina. A preferred GFRα3 agonist is Neublastin. Neublastin may be administered to the eye using protein formulations, in vivo or ex vivo gene therapy, or implantation of encapsulated cells delivering Neublastin locally to the retina. | 2008-10-23 |
20080260703 | Treatment of Insulin Resistance and Diabetes - Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells. Another aspect comprises modifying said host to allow for concurrent insulin sensitization and upregulated production of insulin. | 2008-10-23 |
20080260704 | Combination Treatment of Cardiovascular Disease - Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy. | 2008-10-23 |
20080260705 | Preventing Arrhythmias Associated with Cell Transplantation - Skeletal myoblasts are an attractive cell type for transplantation since they are autologous and resistant to ischemia. However, clinical trials of myoblasts transplantation in heart failure have been plagued by ventricular tachy-arrhythmias and sudden cardiac death. The pathogenesis of these arrhythmias is poorly understood, but may be related to the fact that skeletal muscle cells, unlike heart cells, are electrically isolated by the absence of gap junctions. An in vitro model of myoblasts transplantation into cardiomyocyte monolayers can be used to investigate the mechanisms of transplant-associated arrhythmias. Co-cultures of human skeletal myoblasts and rat cardiomyocytes result in reentrant arrhythmias (spiral waves) that reproduce the features of ventricular tachycardia seen in patients receiving myoblasts transplants. These arrhythmias can be terminated by nitrendipine, an L-type calcium channel Mocker, but not by the Na channel blocker lidocaine. Genetic modification of myoblasts to stably express the gap junction protein connexin 43 decreases arrhythmogenicity in co-cultures. It similarly can be used to increase the safety of myoblasts transplantation in patients. | 2008-10-23 |
20080260706 | Transient Transfection with RNA - A method of mRNA production for use in transfection is provided, that involves in vitro transcription of PCR generated templates with specially designed primers, followed by polyA addition, to produce a construct containing 3′ and 5′ untranslated sequence (“UTR”), a 5′ cap and/or Internal Ribosome Entry Site (IRES), the gene to be expressed, and a polyA tail, typically | 2008-10-23 |
20080260707 | Isolated homozygous stem cells, differentiated cells derived therefrom and materials and methods for making and using same - The present invention discloses and describes pluripotent homozygous stem (HS) cells, and methods and materials for making same. The present invention also provides methods for differentiation of HS cells into progenitor (multipotent) cells or other desired cells, groups of cells or tissues. Further, the applications of the HS cells disclosed herein, include (but are not limited to) the diagnosis and treatment of various diseases (for example, genetic diseases, neurodegenerative diseases, endocrine-related disorders and cancer), traumatic injuries, cosmetic or therapeutic transplantation, gene therapy and cell replacement therapy. | 2008-10-23 |
20080260708 | METHODS AND RELATED SYSTEMS AND FORMULATIONS TO NORMALIZE AND IMPROVE HUMAN BODY CHEMISTRY AND HEALING ABILITY - Methods, systems and formulations for normalizing and improving human body chemistry and the body's natural ability to heal itself. In one embodiment a system including effective amounts of a digestive enzyme, soluble and insoluble fiber, laxative, probiotics, vitamin C, potassium, protease enzymes, lipase, lysine, taurine, proline, choline, inositol, inositol hexaphosphate, policosanol, charcoal, bentonite clay, thyme, ascorbic acid, magnesium citrate, calcium citrate, methylsulfonyl methane, cayenne pepper, magnesium, potassium, ester-c, ginger and niacin, lysine calcium, stevia leaf, citric acid, a tincture of bayberry bark, juniper berries, yam root, cramp bark, golden seal root, fennel seed, uva ursi leaves, ginger root, lobelia herb, catnip herb, and peppermint leaf, golden seal root, Echinacea angustifolia root, ginger root, and licorice root, a tincture of black walnut hulls, venus fly trap, chaparral, wormwood, licorice root, slippery elm, cloves and comfrey root, burdock root, sheep sorrel, rhubarb root, slippery elm, olive leaf and yarrow flower is provided. | 2008-10-23 |
20080260709 | CHOLESTEROL-LOWERING AGENTS, SECONDARY BILE ACID PRODUCTION INHIBITORS AND FOODS AND DRINKS - Secondary bile acid production inhibitors and cholesterol-lowering agents containing a yeast as the active ingredient. | 2008-10-23 |
20080260710 | Method for Suppressing Surgical Site Infection and Column to be Used for the Method - An object of the present invention is to provide a method for suppressing surgical site infections (SSI) that have occurred at extremely high incidence rates at the time of surgical operations and particularly surgical operations on digestive system organs, and to provide a column to be used for the method. According to the present invention, a method is provided for suppressing surgical site infections, which comprises the steps of: (a) administering a chemotherapeutic drug for treating and/or preventing a surgical site infection; and (b) collecting blood from a surgical subject and removing leukocytes that comprise neutrophils from the blood during or within 24 hours after surgical operation, and then returning the blood from which the leukocytes have been removed to the surgical subject. The present invention also provides a column for blood circulation which is filled with a carrier having affinity for leukocytes comprising neutrophils, which is used for suppressing a surgical site infection during or within 24 hours after surgical operation on a digestive system organ. | 2008-10-23 |
20080260711 | Detoxifizyme with Activity of Transforming Aflatoxin and the Gene Encodes Thereof - The present invention relates to a detoxifizyme with the activity of transforming aflatoxin and the gene encodes thereof. Inventors firstly isolate and purify a novel protein, named aflatoxin-detoxifizyme (ADTZ), which has the activity of transforming aflatoxin. The primes specify to the ADTZ gene are obtained through purification and sequencing. The gene encoding of ADTZ is cloned from the total RNA of | 2008-10-23 |
20080260712 | Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability - A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. Methods and devices for enhancing the body's own efforts to stabilize discs in scoliotic spines by increasing collagen crosslinks. This stability enhancement is caused by reducing the bending hysteresis and increasing the bending stiffness of scoliotic spines, by injecting non-toxic crosslinking reagents into the convex side of discs involved in the scoliotic curve. Alternatively, contact between the tissue and the crosslinking reagent is effected by placement of a time-release delivery system directly into or onto the target tissue. Methods and devices that use crosslinking agents for increasing the permeability of an intervertebral disc, improving fluid flux to the intervertebral disc, and increasing the biological viability of cells within the intervertebral disc are provided. | 2008-10-23 |
20080260713 | Neukinase, A Downstream protein of neuregulin - The present invention relates to neukinase, a downstream protein kinase in the neuregulin signaling pathway. In certain aspects, the present invention provides isolated neukinase-encoding nucleic acids, neukinase polypeptides, oligonucleotides that hybridize to neukinase nucleic acids, and expression vectors containing neukinase-encoding sequences. The present invention further provides isolated host cells, antibodies, transgenic non-human animals, compositions, and kits relating to neukinase. In other aspects, the present invention further provides methods of identifying predisposition to cardiac dysfunction, methods of detecting the presence of neukinase, neukinase nucleic acid, methods of screening for agents which affect neukinase activity, and methods of modulating neukinase activity. | 2008-10-23 |
20080260714 | Fibrin Compositions Containing Strontium Compounds - A composition for use in bone healing and bone regeneration in the form of a viscoelastic hydrogel gel or liquid formulation comprising fibrinogen, thrombin and an inorganic component comprising a strontium (Sr) containing compound and/or possibly another metal such as a calcium containing compound. The strontium containing compound can be dissolved in the thrombin solutions or added to the clot in crystalline particulate form. Upon mixing the components, gelation takes place to form a matrix. The composition may also comprise an iodine-containing compound which acts as a plasticizer. | 2008-10-23 |
20080260715 | Precursor N-acetylgalactosamine-4 sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme - The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant precursor enzyme to a highly purified form. | 2008-10-23 |
20080260716 | Method and Composition for High Level Disinfection Employing Quaternary Ammonium Compounds - Methods and compositions for high level disinfection (as herein defined) of a surface. Methods include treating the surface with a composition including a quaternary ammonium compound in a concentration which exceeds 1% w/w and the temperature of treatment is in the range of from 30° C. to 80° C. A log (6) reduction in | 2008-10-23 |
20080260717 | Methods for Reducing Seizure-Induced Neuronal Damage - This invention provides a method for treating a subject either during or soon after a seizure, in order to reduce the extent of neuronal damage in the subject resulting from the seizure comprising administering to the subject, either during or soon after the seizure, a therapeutically effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE), so as to thereby reduce the extent of neuronal damage in the subject. This invention further provides a method for inhibiting neuronal damage which would otherwise result from a seizure in a subject predisposed to having a seizure, comprising administering to the subject a prophylactically effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE), so as to inhibit neuronal damage which would otherwise result from a seizure in the event the subject were to suffer a seizure. | 2008-10-23 |
20080260718 | Phospholipase C Gamma Modulation and Uses Thereof for Management of Pain and Nociception - The present invention provides methods of preventing and treating pain, by modulating, e.g. inhibiting, the activity, function and/or expression of a PLC | 2008-10-23 |
20080260719 | EDG: Modulators of lymphocyte activation and migration - The present invention relates to regulation of lymphocyte activation and migration. More particularly, the present invention is directed to nucleic acids encoding EDG family GPCR proteins, e.g., EDG-1, 2, 3, 4, 5, 6, 7, or 8, which are involved in modulation of lymphocyte activation and migration. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, sphingolipid analogs, and ribozymes, that modulate lymphocyte activation or migration via modulation of EDG GPCRs and EDG related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to lymphocyte activation and suppression, and lymphocyte migration. | 2008-10-23 |
20080260720 | Systems and Methods for Inhibiting Metastasis - The present invention relates to compositions and methods for cancer therapeutics. In particular, the present invention provides compositions and methods for inhibiting cancer metastasis by inhibiting G12 and G13 activity. | 2008-10-23 |
20080260721 | Nucleic acids encoding a mammalian raptor polypeptide and uses therefor - The present invention relates to isolated raptor nucleic acid molecules of mammalian origin (e.g., human) and complements, portions and variants thereof. Another aspect of the invention are isolated raptor polypeptides of mammalian origin and portions thereof, and antibodies or antigen binding fragments thereof that specifically bind a raptor polypeptide. The present invention also relates to constructs and host cells comprising the nucleic acid molecules described herein. In addition, the present invention relates to uses of the nucleic acid and polypeptide molecules provided herein. | 2008-10-23 |
20080260722 | Method for High Efficiency Survival/Proliferation of Human Embyonic Stem Cells and Human Embryo Survival in Culture - The present invention provides a role for neurotrophins in hES cell survival and important new insights into the molecular mechanisms controlling the growth of these cells. Although previous studies identified growth factors that affect self-renewal of hES cells, the novelty of the present invention is the identification of factors that act through specific receptors present on hES cells and activate the receptors at physiological concentrations to promote survival and proliferation. | 2008-10-23 |
20080260723 | Method of Treatment and Bioassay Involving Macrophage Migration Inhibitory Factor (MIF) as Cardiac-Derived Myocardial Depressant Factor - One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor. | 2008-10-23 |
20080260724 | Drug Induced Exposure Of The Fungal Pro-Inflammatory Molecule Beta-Glucan - Methods and reagents for screening for anti-microbial agents are provided. Diagnostic tools for assessing treatment of fungal infections are provided. Antimicrobial substances including substances useful for the treatment of fungal infections are provided. In some embodiments, the substances have antigen unmasking activity. In some embodiments the substances have fungicidal activity and surface antigen unmasking activity. | 2008-10-23 |
20080260725 | Tag and target delivery system - A system for targeting dividing cells and delivering therapeutic agents to the targeted cells using a Tag nanoparticle. Each Tag nanoparticle comprises a nucleotide encoding a Tag, which is expressed only in dividing cells. The system optionally utilizes a microparticle to deliver Tag nanoparticles to cells. Therapeutic nanoparticles comprising therapeutic compounds are subsequently targeted to the tagged cells via surface molecules that specifically bind to the Tag. The system may be adapted for specific patient needs, for example, targeting and eliminating cancer cells, preventing metastasis and secondary tumors, stimulating or inhibiting proliferation of endothelial cells, and stimulating cell regeneration in diseased organs such as liver. | 2008-10-23 |
20080260726 | Organic Compounds - A method of identifying a substance suitable for use in inhibiting mucus hypersecretion that modulates the activity of a human cathepsin C gene or its gene product. The method involves combining a candidate substance with the human cathepsin C gene or its gene product and measuring the effect of the candidate substance on the activity of the gene or its gene product. | 2008-10-23 |
20080260727 | Modulation of Nkg2d - The present invention relates to methods and compositions for treating or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells and/or NK cells, by modulating NKG2D. | 2008-10-23 |
20080260728 | Treatment of Severe Multiple Sclerosis - Methods of treating multiple sclerosis are disclosed. | 2008-10-23 |
20080260729 | Method of Treating Cancer Comprising a Vegf-B Antgonist - The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue. | 2008-10-23 |
20080260730 | Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies - The present invention provides a method of treating autoimmune diseases. In particular, it provides a method for the treatment of Crohn's disease or psoriasis comprising administering to a subject in need thereof a therapeutically effective amount of an antibody against interferon γ. | 2008-10-23 |
20080260731 | OPTIMIZED ANTIBODIES THAT TARGET CD19 - The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention. | 2008-10-23 |
20080260732 | CHIMERIC AND HUMANIZED ANTIBODIES TO ALPHA5BETA1 INTEGRIN THAT MODULATE ANGIOGENESIS - The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same. | 2008-10-23 |
20080260733 | HUMANIZED COLLAGEN ANTIBODIES AND RELATED METHODS - The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis. | 2008-10-23 |
20080260734 | COMPOSITIONS AND METHODS FOR CHARACTERIZING, REGULATING, DIAGNOSING, AND TREATING CANCER - The present invention relates to compositions and methods for characterizing, regulating, diagnosing, and treating cancer. For example, the present invention provides compositions and methods for inhibiting tumorigenesis of certain classes of cancer cells, including breast cancer cells and preventing metastasis. The present invention also provides systems and methods for identifying compounds that regulate tumorigenesis. | 2008-10-23 |
20080260735 | Transfer request (37 CFR 1.821(e)) humanised antibodies to the epidermal growth factor receptor - The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular in the treatment of cancer. | 2008-10-23 |
20080260736 | Methods and Compositions to Regulate Iron Metabolism - The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders. | 2008-10-23 |
20080260737 | COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE - The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases. | 2008-10-23 |
20080260738 | SINGLE CHAIN FC, METHODS OF MAKING AND METHODS OF TREATMENT - The present invention relates generally to scFc molecules. The scFc molecules comprise at least two Fc regions and at least one linker, and can be produced in a variety of single chain configurations. The scFc molecules can further comprise at least one binding entity and/or at least one functional molecule. Binding entities can be fused to the scFc molecule in a variety of configurations. The present invention also relates generally to methods for making such molecules and methods for their use. The scFc molecules provided herein can be recombinantly produced. Also provided are monovalent forms of the scFc molecules that have an equivalent or superior ADCC and/or CDC response than do bivalent molecules targeting the same antigens. Provided herein are improved antigen binding compositions. Methods for using the scFc molecules of the present inventions are provided | 2008-10-23 |
20080260739 | Use of Anti-Mortalin 2 Antibody and Functional Nucleic Acid for Cancer Therapies - The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific anti-mortalin antibody, was injected into a tumor of a nude mouse, tumor growth was suppressed or the tumor shrank compared with the case of a control. In accordance with the present invention, the use of a specific anti-mortalin antibody (K antibody) for tumor therapies and the use of such antibody as a carrier molecule for transportation of immunotoxicin and the like into cells are provided. It has been shown that mortalin can be a target for cancer therapies. In accordance with the present invention, a novel and effective anticancer agent is provided. In addition, an anti-mortalin antibody that is internalized by cells is developed. Thus, various applications using such antibody are provided. | 2008-10-23 |
20080260740 | Anti-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer - Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells. | 2008-10-23 |
20080260741 | Preventive and/or Therapeutic Agent for Cancer - As the results of intensive studies aiming at providing a gene targeting a cancer cell or a cancer tissue, novel nucleotide sequences showing increased expression in a cancer cell or a cancer tissue compared with normal tissues are identified. As the results of the subsequent studies, genes showing increased expression in a cancer cell or a cancer tissue which are useful as a drug discovery target are found out. | 2008-10-23 |
20080260742 | Preventives/Remedies for Cancer - The present invention provides preventives/remedies for cancer and so on. Specifically, an antibody against a protein comprising the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 17, SEQ ID NO: 25, SEQ ID NO: 38 or SEQ ID NO: 48, a compound that inhibits the expression of the above protein or the expression of a gene for the above protein, and so on, are useful as preventives/remedies for cancer, etc., cancer cell apoptosis promoters, cancer cell growth inhibitors, and so on. | 2008-10-23 |
20080260743 | Means and Methods for Detecting Methylated Dna - The present application relates to a nucleic acid molecule having a nucleotide sequence encoding a bifunctional polypeptide comprising the DNA-binding domain of a protein belonging to the family of Methyl-CpG binding proteins (MBDs) and the Fc portion of an antibody. In addition, vectors and host cells which comprise said nucleic acid molecule and polypeptides which are encoded by said nucleic acid molecule as well as processes for producing said polypeptide are disclosed. Moreover, the present application provides an antibody specifically binding said polypeptide and compositions, in particular diagnostic compositions comprising the nucleic acid molecule(s), vector(s), host cell(s), polypeptide(s) or antibodie(s) of the present application. Furthermore, methods and uses employing the polypeptides of the present invention for detecting methylated DNA, in particular in tumorous tissue or tumor cells are provided. | 2008-10-23 |
20080260744 | G PROTEIN COUPLED RECEPTORS AND USES THEREOF - The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels. | 2008-10-23 |
20080260745 | TARGETED IDENTIFICATION OF IMMUNOGENIC PEPTIDES - This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody. | 2008-10-23 |
20080260746 | Erythropoietin Polypeptides and Uses Thereof - The present invention relates to EPO polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample. | 2008-10-23 |
20080260747 | Methods and Materials Relating to CD84-like Polypeptides and Polynucleotides - The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides. | 2008-10-23 |
20080260748 | Methods for Damaging Cells Using Effector Function of Anti-Dsc2 Antibody - The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides methods and pharmaceutical compositions that comprise anti-DSC2 antibody as an active ingredient for damaging DSC2-expressing cells via the effector function of the antibody. | 2008-10-23 |
20080260749 | Novel Tetrahydropyridothiophenes - Compounds of a certain formula (I) | 2008-10-23 |
20080260750 | Polynucleotides Encoding Acetylcholine-Gated Chloride Channel Subunits of Caenorhabditis Elegans - The invention relates to novel polynucleotides which encode novel polypeptides that are acetylcholine-gated chloride channel subunits and immunogenic or acetylcholine-binding fragments thereof. The novel polypeptides may be used for identifying compounds that modulate the acetylcholine-gated chloride channels, e.g. for use as pesticides and antiparasitic agents. Methods for identifying compounds that modulate the acetylcholine-gated chloride channels are provided. | 2008-10-23 |
20080260751 | Methods and Compositions for the Modulation of Immune Responses and Autoimmune Diseases - The present invention relates to a regulation of inflammation and immune responses. The present invention relates to a method of treating a condition comprising administering a pharmaceutically effective amount of an activator of RP105. The condition is typically associated with TLR-4 activation and cytokine production. Conditions addressed by the invention include sepsis, septic shock, inflammation, rheumatoid arthritis and Crohn's disease. The invention also provides the use of an activator of RP105 in the manufacture of a medicament for use in the treatment of a condition associated with cytokine production and methods for identifying an activator of RP105, which is also suitable for use in the treatment of a condition associated with stimulus-induced cytokine production. More specifically the patent relates to the use of RP105 as a specific inhibitor of TLR4 signaling and as a physiological regulator of TLR4 signaling for the treatment of TLR4-mediated inflammation and immune-related diseases. This invention also relates to treating a subject having a disease or condition associated with Toll-like receptor 4. | 2008-10-23 |
20080260752 | PREVENTION AND REDUCTION OF BLOOD LOSS - Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass. | 2008-10-23 |
20080260753 | Mouse Models of Crohn's Disease and a Method to Develop Specific Therapeutics - Provided are compositions, transgenic animals and methods for screening and analyzing agents useful for treating inflammatory bowel diseases. Also provided are methods to treat inflammatory bowel disease, Crohn's disease and Blau syndrome. | 2008-10-23 |
20080260754 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful. | 2008-10-23 |
20080260755 | Proteolytically cleavable fusion proteins with high molar specific activity - The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV. | 2008-10-23 |
20080260756 | Peptide Inhibitors of iASPP - The invention relates to a polypeptide or part thereof which inhibits the apoptotic activity of the tumor suppressor protein p53, and includes screening methods to identify agents which interfere with the activity of the polypeptide. | 2008-10-23 |
20080260757 | Bispecific Fusion Antibodies With Enhanced Serum Half-Life - Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent. | 2008-10-23 |
20080260758 | UNIVERSAL GM-CSF EXPRESSING BYSTANDER HUMAN K562 CELL LINE - The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition. | 2008-10-23 |
20080260759 | Novel Mite Allergen - A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity. | 2008-10-23 |
20080260760 | Prostate-Specific Antigen-Derived Mhc Class H-Restricted Peptides and Their Use in Vaccines to Treat or Prevent Prostate Cancer - The present invention relates to immunogenic peptides derived from human prostate cancer antigen (PSA-derived peptides) and their use as vaccines to treat or prevent prostate cancer. The invention is also related to dendritic cells from a patient having prostate cancer, which dendritic cells have been exposed to one or more PSA-derived peptides, and their use to treat or prevent prostate cancer in the patient. The invention is also directed to T-cells from a patient which cells are specific for PSA-activated peptide(s), and their uses to treat or prevent prostate cancer. | 2008-10-23 |
20080260761 | Compositions, Splice Variants and Methods Relating to Cancer Specific Genes and Proteins - The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research. | 2008-10-23 |
20080260762 | HLA binding motifs and peptides and their uses - The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. | 2008-10-23 |
20080260763 | High Throughput Proteomics - Methods to obtain expression systems and proteins in a high-throughput protocol by utilizing mixtures of cells cultured from those transformed with a desired nucleotide sequence permit rapid production of protein for use in arrays to assess activity. In one embodiment, the proteins (or peptides) in the array are assessed for their immunological activity with regard to an infectious agent. | 2008-10-23 |
20080260764 | REPLIKIN PEPTIDES AND USES THEREOF - The present invention provides isolated influenza peptides and nucleic acid sequences and methods of identifying said influenza peptides and nucleic acid sequences having a pattern of substitution of amino acids or nucleic acids in highly conserved Replikin and Replikin Scaffold sequences that is predictive of rapid replication and virulence. Methods of predicting virulence in emerging influenza strains are provided comprising identifying peptides and nucleic acid sequences having the predictive pattern of substitution. | 2008-10-23 |
20080260765 | HPV DNA Vaccines and Methods of Use Thereof - Human papillomavirus (HPV) infection is the etiological factor for cervical cancer. Provided are HPV vaccines that generate a humoral immune response to prevent new infection, as well as cell-mediated immunotherapy to eliminate established infection or HPV-related disease. HPV vaccines include nucleic acid sequences encoding HPV16 early proteins E6 and E7. Additional nucleic acid sequences in the vaccines include sequences encoding calreticulin and/or the HPV16 late protein L2. Methods using these vaccines are provided that result in therapeutic effects. | 2008-10-23 |
20080260766 | Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti-HIV-1 prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention - The present invention refers to new epitopes recognized by CD4+ T-lymphocytes. In addition, the present invention refers to the uses of such epitopes and their combinations, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. | 2008-10-23 |
20080260767 | Novel Protein Which can be Used, in Particular, for the In Vitro Isolation and Prevention of Legionella Pneumophila Infections - The invention relates to novel polynucleotides, including SEQ ID NO: 1 or parts or variants of the sequence, novel polypeptides encoded by the polynucleotides, expression vectors including the polynucleotides and host cells including the expression vectors. The polynucleotides and polypeptides can be used in the field of in vitro diagnosis and/or for production of vaccines against | 2008-10-23 |
20080260768 | Streptococcus pneumoniae proteins and nucleic acid molecules - Protein antigens from | 2008-10-23 |
20080260769 | Polypeptides for Oligomeric Assembly of Antigens - A system for expressing antigenic polypeptides in oligomeric form fuses the antigenic polypeptide to an oligomerisation polypeptide such that the oligomerisation polypeptide can interact with other oligomerisation polypeptides and bring multiple copies of the antigenic polypeptide into close proximity in the form of an oligomer. Expressing the polypeptides in oligomeric form in this way can improve their immunogenicity compared to a monomeric form. | 2008-10-23 |
20080260770 | Use of Tellurium Compounds as Adjuvants - Methods for enhancing the immune response of a subject to an immunoeffector, and methods of enhancing interleukin-12 production, which are effected by administering an amount of the immunoeffector and an effective adjuvanting amount of a tellurium-containing compound are provided. The enhanced immune response may be a cell-mediated or a humoral immune response. A pharmaceutical composition, which comprises the tellurium-containing compound, the immunoeffector and a pharmaceutically acceptable carrier is also provided. Use of a tellurium-containing compound as an adjuvant for immunization is also provided. | 2008-10-23 |
20080260771 | PROSTATE DISORDER(S) PHYTO-NUTRACEUTICAL SYNERGISTIC COMPOSITION - A Phyto-nutraceutical composition for the prevention and treatment of prostate disorders is provided. A specific combination of extracts of plants and nutraceuticals is provided, based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combinations have synergistic effects, with minimal side effect. | 2008-10-23 |
20080260772 | Extract From Agaricus Blazei Murill Capable of Suppressing Breast Cancer - A food material capable of suppressing the genesis of breast cancer or proliferation of terminal breast cancer. An extract of | 2008-10-23 |
20080260773 | Saccharide Conjugate Vaccines - The invention provides compositions comprising a combination of two or more monovalent conjugates, each of said two or more monovalent conjugates comprising a carrier protein comprising T cell epitopes from two or more pathogens conjugated to saccharide antigen. The invention also provides a multivalent conjugate comprising two or more antigenically distinct saccharide antigens conjugated to the same carrier protein molecule, wherein the carrier protein comprises T cell epitopes from two or more pathogens. Further compositions comprise one or more of said monovalent conjugates and one or more of said multivalent conjugates. The invention further provides methods for making said compositions and uses for said compositions. | 2008-10-23 |
20080260774 | Alpha-galactosyl ceramide analogs and their use as immunotherapies - The present disclosure relates to synthetic alpha-galactosyl ceramide (α-GalCer) analogs, and their use as immunotherapies. In one aspect, a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1: | 2008-10-23 |
20080260775 | New Live Virus Vaccines - The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an immune response by administration of the same to a subject. | 2008-10-23 |
20080260776 | Preparation of Salmonella Broad-Spectrum Vaccines - The present invention relates to a pharmaceutical composition providing protective unity against a broad spectrum of | 2008-10-23 |
20080260777 | COMPOSITION AND METHOD FOR CONTROLLING INTESTINAL PATHOGENIC ORGANISMS - An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes seven field strains of | 2008-10-23 |
20080260778 | Method of Vaccination Against Testicular Bvdv Infection - The methods of the invention relate to methods for preventing testicular infection by bovine viral diarrhea virus by immunizing susceptible male animals against infection. | 2008-10-23 |
20080260779 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 2008-10-23 |
20080260780 | MATERIALS AND METHODS RELATING TO IMPROVED VACCINATION STRATEGIES - The invention provides novel vaccination strategies based on a prime-boost vaccination regiment. The inventors have determined improved ways of boosting an immune response in a patient previously primed or exposed to a plurality of epitopes. The improved method requires the epitopes in the boosting phase to be administered individually, i.e. held on separate peptide constructs. | 2008-10-23 |
20080260781 | PROTEOSOME INFLUENZA VACCINE - Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included. | 2008-10-23 |
20080260782 | Mycobacterium avium subspecies paratuberculosis vaccines and methods of using the same - The invention relates to vaccine compositions composed of at least one | 2008-10-23 |